NYSE - Nasdaq Real Time Price USD

Takeda Pharmaceutical Company Limited (TAK)

13.24

+0.09

(+0.65%)

As of 11:30 AM EDT. Market Open.

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

OSAKA, Japan & CAMBRIDGE, Mass., April 18, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.1 The subcutaneous administration of ENTYVIO was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately to

Business Wire 16 hours ago
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

CAMBRIDGE, Mass., April 08, 2024--Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program. To create greater impact and foster equity in under-resourced communities, the company is focusing its philanthropic efforts on the two areas of Food is Health and Building STEM (Science, Technology, Engineering and Math) Foundations and p

Business Wire 11 days ago
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.

PR Newswire 23 days ago
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

OSAKA, Japan & CAMBRIDGE, Mass., March 26, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024.

Business Wire 23 days ago
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass., March 26, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAM

Business Wire 24 days ago
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

OSAKA, Japan & CAMBRIDGE, Mass., March 19, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete

Business Wire 30 days ago
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs). Under

GlobeNewswire last month
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

OSAKA, Japan & CAMBRIDGE, Mass., March 13, 2024--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP). Mezagitamab is a fully human immunoglobulin IgG1 monoclonal antibody (mAb) with high affinity for CD38 expressing cells (including plasmablasts, plasma cells, natur

Business Wire last month
Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.

Takeda (TSE:4502/NYSE:TAK) today announced a strategic partnership with Biological E. Limited, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030[i].

PR Newswire last month
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

CAMBRIDGE, Mass. & HYDERABAD, India, February 27, 2024--Takeda (TSE:4502/NYSE:TAK) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs. MDVs of

Business Wire last month
Championing Rare Voices on Rare Disease Day

February 29th marks Rare Disease Day. On the rarest day of the year, we are reminded of the reality that 1 in 12 Canadians will be impacted by rare disease in their lifetime.1 A critical need exists to create meaningful change and action for the growing rare disease community in Canada.

CNW Group last month
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

OSAKA, Japan & CAMBRIDGE, Mass., February 12, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

Business Wire 2 months ago
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

OSAKA, Japan & CAMBRIDGE, Mass., February 08, 2024--Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024

Business Wire 2 months ago
Takeda Announces Chief Financial Officer Succession

OSAKA, Japan & CAMBRIDGE, Mass., February 01, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos will step down as CFO, effective April 1, 2024 and will remain with the company as a board director until June 28, 2024. Milano Furuta, president of Takeda’s Japan Pharma Business Unit (JPBU), will succeed Mr. Saroukos, effective April 1, 2024. Mr.

Business Wire 2 months ago
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

OSAKA, Japan & CAMBRIDGE, Mass., February 01, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-to-date strong momentum in its Growth & Launch Products (+12.7% at CER) offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year Management Guidance.

Business Wire 2 months ago
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development ...

ACCESSWIRE 2 months ago
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass., January 29, 2024--U.S. Food and Drug Administration (FDA) approves GAMMAGARD LIQUID for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

Business Wire 2 months ago
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass., January 29, 2024--Takeda announced that the EC approved HYQVIA as maintenance therapy in patients of all ages with CIDP after stabilization with IVIG.

Business Wire 2 months ago
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation

Cognizant (NASDAQ: CTSH) announced today an expanded agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support the company's digital transformation strategy by reinforcing and supporting its technology efforts. Together, Takeda and Cognizant will embark on a new project to attract additional technology talent and help Takeda further expand its Innovation Capability Center operations.

PR Newswire 2 months ago
Takeda Named Global Top Employer for Seventh Consecutive Year

OSAKA, Japan & CAMBRIDGE, Mass., January 18, 2024--Takeda announced that it has received global Top Employer certification for 2024. It is one of just 17 companies that received global recognition.

Business Wire 2 months ago

Performance Overview

Return	TAK	Nikkei 225
YTD	-7.18%	+10.77%
1-Year	-20.74%	+29.58%
3-Year	-22.45%	+24.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Takeda Pharmaceutical Company Limited (TAK)

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Championing Rare Voices on Rare Disease Day

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Announces Chief Financial Officer Succession

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation

Takeda Named Global Top Employer for Seventh Consecutive Year

Performance Overview